Dr. Andreopoulou on the Impact of Immunotherapy in TNBC

Dr. Andre on Questions With Immunotherapy in Triple-Negative Breast CancerПодробнее

Dr. Jhaveri Discusses the Potential of Immunotherapy in TNBCПодробнее

Dr. Cynthia Ma on Immunotherapy in TNBCПодробнее

IMpassion130: immunotherapy for TNBCПодробнее

Eleni Andreopoulou, ASCO 2019 - Immunotherapy in Breast Cancer (Part 2)Подробнее

Dr. Nanda on Immunotherapy in Metastatic TNBCПодробнее

Eleni Andreopoulou, ASCO 2019 - Immunotherapy in Breast Cancer (Part 1)Подробнее

Dr. Adams on Immunotherapy in Triple-Negative Breast CancerПодробнее

Eleni Andreopoulou, ASCO 2018 – Advances in molecular therapy in triple-negative breast cancerПодробнее

Emerging immunotherapy beyond checkpoint inhibitors for TNBCПодробнее

Chemo-immunotherapy for TNBCПодробнее

TNBC: work to be doneПодробнее

IMpassion130 Data Demonstrate Clinical Benefit for Immunotherapy in Metastatic TNBCПодробнее

TNBC: immunotherapy in the neoadjuvant settingПодробнее

Immunotherapy for TNBCПодробнее

KEYNOTE-522 Demonstrates Potential for Immunotherapy in Triple-Negative Breast CancerПодробнее

Strategies to improve the response to immunotherapy in TNBCПодробнее

Neoadjuvant Immunotherapy in TNBC and Targeted LND in Breast Cancer: 2023 Best of Breast ConferenceПодробнее

New directions in immunotherapy for improving outcomes in TNBCПодробнее